Accretion Nutraveda — 360° view

Accretion Nutraveda, a company in the Pharmaceuticals industry, reported revenue of ₹29 crore and net profit of ₹4.73 crore for the September 2026 quarter.

Accretion Nutraveda (BSE: ANL) closed at ₹320.00 on 20 Nov 2026. Its market capitalisation is ₹232 crore and it trades at 31.2 times earnings.

Share price
₹320.00 (20 Nov 2026)
Market cap
₹232 Cr (20 Nov 2026)
P/E
31.22 (20 Nov 2026)
Revenue
₹29 Cr (September 2026 quarter)
Net profit
₹5 Cr (September 2026 quarter)
ROCE
27.7% (FY26)
ROE
25.0% (FY26)
Book value
₹55.5 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹360.00 / ₹150.10 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: ANL

Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.